Anteris Technologies Global Corp. — Board/Management Information 2022

May 23, 2022

ASX ANNOUNCEMENT

24 May 2022

EXPANSION OF MEDICAL ADVISORY BOARD

Brisbane, Australia and Minneapolis, USA. Anteris Technologies Ltd (ASX: AVR; Anteris or the Company ) welcomes Associate Professor Dion Stub MBBS, PhD, FRACP of the Alfred Hospital and Monash University to Anteris’ Australian Medical Advisory Board.

Associate Professor Dion Stub specialises in structural heart procedures, including angioplasty, aortic valve replacement (TAVI), and balloon valvuloplasty. He has further special interests in treating myocardial infarction and cardiac arrest, particularly with interventional methods.

Based in Melbourne, Associate Professor Stub is a highly experienced interventional cardiologist, having performed thousands of cardiac procedures, helping patients experience life to the fullest again.

His Medical Advisory Board participation is a welcome addition as we continue building clinical validation for our novel DurAVR™ 3D single-piece transcatheter aortic heart valve system.

“We are very pleased Associate Professor Stub is joining our Australian Medical Advisory Board. His significant TAVI experience and ongoing contributions will greatly enhance our commercialisation and market development efforts in Australia,” Anteris CEO Wayne Paterson said.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris’ DurAVR[™] 3D single-piece aortic heart valve replacement addresses the needs of tomorrow’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.

The proven benefits of its patented ADAPT[®] tissue technology, paired with the unique design of our DurAVR[™] 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066 Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

==> picture [95 x 51] intentionally omitted <==

Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

For more information:

Hannah Howlett WE Communications E: WE-AUAnterisTech@we-worldwide.com

P: +61 4 5064 8064 www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

LinkedIn: https://www.linkedin.com/company/anteristech

==> picture [95 x 52] intentionally omitted <==